Effekten af GCP-direktivet på forskerinitierede kliniske laegemiddelforsøg--sekundaerpublikation

Louise Berendt, Cecilia Håkansson, Karin Friis Bach, Kim Dalhoff, Per Buch Andreasen, Lene Birgitte Grejs Petersen, Elin Andersen, Henrik Enghusen Poulsen

    Abstract

    Since 2004, adherence to Good Clinical Practice has been mandatory for all clinical drug trials. This was new to the investigator-initiated trials. Our study showed no association between the implementation of the Directive and investigator or industry-initiated trials. However, a steady decline was observed over the entire period. Presumably, the introduction of GCP did not entail a decline because of the presence of GCP units at university hospitals. Thus, researchers can conduct clinical drug trials under the same regulations as drug companies.
    Bidragets oversatte titel[Effect of the GCP Directive on academic drug trials]
    OriginalsprogDansk
    TidsskriftUgeskrift for Laeger
    Vol/bind170
    Udgave nummer33
    Sider (fra-til)2437-9
    Antal sider3
    ISSN0041-5782
    StatusUdgivet - 11 aug. 2008

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Effekten af GCP-direktivet på forskerinitierede kliniske laegemiddelforsøg--sekundaerpublikation'. Sammen danner de et unikt fingeraftryk.

    Citationsformater